Rasilez approval spurs Novartis expansion

Bolstered by the EU's blessing on its new hypertension treatment Rasilez, Novartis is planning a €183 million ($250 million) expansion of a plant near Basel, Switzerland. The expansion will boost production capacity of several high blood pressure meds, including top-seller Diovan and, of course, Rasilez.

Approved under the U.S. brand name Tekturna in March, Rasilez is a first-in-class treatment that targets renin, an enzyme that can trigger high blood pressure.

- check out the announcement on the approval
- and read this report

Related Articles:
FDA approves Novartis' Tekturna. Report
Novartis files for FDA approval of Rasilez. Report
Novartis maps $100M R&D complex in China. Report
Novartis to build $600M flu plant in N.C. Report 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

North Korean hackers were accused of posing as corporate recruiters in a scheme to breach AstraZeneca's computer systems and steal COVID-19 research.

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

McKinsey & Company helped guide Purdue's strategy for years and pitched the idea of rebates to distributors for overdoses, according to the NYT.